- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Eye on Pharma: Daewoong Launches Samsung Bioepis' Trastuzumab Biosimilar
The trastuzumab biosimilar is priced 29.5% below the list price for the trastuzumab reference product, Herceptin.
According to Korean news media, Daewoong Pharmaceutical, a Korean-based bioengineering company, announced yesterday that it has launched a trastuzumab biosimilar the Republic of Korea, sold as Samfenet. Daewoong secured exclusive sales rights for the biosimilar from drug developer, Samsung Bioepis in December 2017.
The trastuzumab biosimilar is priced 29.5% below the list price for the trastuzumab reference product, Herceptin, owned by Roche subsidiary Genentech. In 2016, Herceptin was the world’s eighth best-selling drug, with global sales of $6.7 billion. With the addition of Samfenet, Daewoong strengthens its oncology product portfolio that currently includes a chronic myeloid leukemia treatment, Supect (radotinib), and a prostate cancer drug, Luphere Depot (leuprolide acetate).
Samfenet will not be the only trastuzumab biosimilar available in the Korean market, as Celltrion launched its own biosimilar molecule, Herzuma, in September 2017. At the time of the first biosimilar’s launch, the list price of the originator Herceptin dropped to 70% of its original price, as is the case automatically after all first biosimilar market entries in the Republic of Korea.
In addition to the Korean market, Samsung Bioepis has its eyes on both the European and United States markets for the biosimilar. In December 2017, Bioepis announced that the FDA accepted its Biologics License Application (BLA) for review. If approved, the drug will be commercialized in the United States by Merck, and would compete not only the reference product, but also with Ogivri, Mylan-Biocon’s recently FDA-approved biosimilar trastuzumab (though Ogivri has yet to be launched, and no date for its launch has been publicized).
In the European Union, in November 2017, the European Commission granted Samsung Bioepis a marketing authorization for the biosimilar, making it the first trastuzumab biosimilar approved in that marketplace. Within both the EU and the European Economic Area member states of Norway, Iceland, and Liechtenstein, the drug will be sold as Ontruzant.
Bioepis also reports a number of other biosimilar products included in its pipeline. The company is currently in the midst of developing the following: SB4, etanercept (referecend on Enbrel); SB2, infliximab (referenced on Remicade); SB5, adalimumab (referenced on Humira); SB9, insulin glargine (referenced on Lantus); and SB8, bevacizumab (referenced on Avastin).
Eye on Pharma: Golimumab Biosimilar Update; Korea Approves Denosumab; Xbrane, Intas Collaboration
December 10th 2024Alvotech and Advanz Pharma have submitted a European marketing application for their golimumab biosimilar to treat inflammatory diseases, while Celltrion secured Korean approval for denosumab biosimilars, and Intas Pharmaceuticals partnered with Xbrane Biopharma on a nivolumab biosimilar.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
The Rebate War: How Originator Companies Are Fighting Back Against Biosimilars
November 25th 2024Few biologics in the US have multiple biosimilar competitors, but originator biologics respond quickly to competition by increasing rebates and lowering net prices, despite short approval-to-launch timelines for biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Overcoming Challenges to Improve Access and Reduce Costs
November 12th 2024Biosimilars hold the potential to dramatically lower health care costs and improve access to life-changing treatments, but realizing this potential will require urgent policy reforms, market competition, and better education for both providers and patients.
Challenges, Obstacles, and Future Directions for Anti-TNF Biosimilars in IBD
November 9th 2024A review article on tumor necrosis factor (TNF)-α inhibitors in inflammatory bowel disease (IBD) outlined current use of anti-TNF originators and biosimilars, their efficacy and safety, the benefits and challenges of biosimilars, and the future of biosimilars in IBD.
